Table 3.

Clinical response at EOI for MRD-negative patients

Clinical response at EOI∗MRD-evaluable patients† (N = 21)
IRC-assessed, n (%) 
CR 16 (76.2) 
PR 3 (14.3) 
SD 2 (9.5) 
NA 0 
INV-assessed, n (%) 
CR 18 (85.7) 
PR 3 (14.3) 
SD 0 
NA 0 
Clinical response at EOI∗MRD-evaluable patients† (N = 21)
IRC-assessed, n (%) 
CR 16 (76.2) 
PR 3 (14.3) 
SD 2 (9.5) 
NA 0 
INV-assessed, n (%) 
CR 18 (85.7) 
PR 3 (14.3) 
SD 0 
NA 0 

NA, not available.

∗

Assessed according to modified Lugano 2014 criteria.

†

Patients with circulating clones at baseline were all MRD negative at EOI (see supplemental Figure 2 for patient flow).

View Large